Keiichi Fujiwara, ESMO 2022: Phase 3 GOTIC-002 LUFT study results – Chemotherapy with tegafur-uracil for locally advanced cervical cancer
Maintenance chemotherapy with oral tegafur-uracil (UFT) after surgery has been shown to prolong survival in lung, breast, gastric and colon cancer. Dr Keiichi Fujiwara (Saitama Medical University International Medical Centre, Saitama, Japan) joins touchONCOLOGY to discuss the phase 3 GOTIC-002 LUFT study results, investigating the efficacy of maintenance chemotherapy using UFT following concurrent chemoradiotherapy for locally advanced cervical cancer.
The abstract entitled ‘Randomized phase III trial of maintenance chemotherapy with tegafur-uracil versus observation following concurrent chemoradiotherapy for locally advanced cervical cancer, GOTIC-002 LUFT trial ‘ Abstract LBA31, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- What was known about the impact of maintenance chemotherapy with tegafur-uracil (UFT) after surgery on cancer survival? (0:43)
- What were the aims, design and eligibility criteria of the GOTIC-002 LUFT study? (1:58)
- What were the study findings in terms of efficacy, safety and tolerability? (2:57)
- Why do you think UFT failed to improve overall survival? (4:10)
- What other GOTIC studies are planned or ongoing? (5:27)
Disclosures: Keiichi Fujiwara receives grant/research support from Taiho; is on the advisory board for Daiichi Sankyo, Seagen, and Genmab; and receives honoraria/honorarium from Kiowa KIRIN.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
